Boehringer Ingelheim

📣 Brainomix Completes £14M ($18M) Series C Round to Advance Its Transformative AI Imaging Technology in Healthcare 📣 The University of Oxford spinout accelerates expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on lifesaving thrombectomy and thrombolytic treatments. Funding will also support clinical uptake of its breakthrough solution in lung fibrosis. Michalis Papadakis, CEO and Co-Founder at Brainomix: “We would like to thank all the investors that participated, including Parkwalk Advisors and Boehringer Ingelheim for their continued support, and welcome Hostplus, all of whom recognize the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients. We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies.” Lord Patrick Vallance, UK Minister of State for Science, Research & Innovation, said: “The AI tools developed by Brainomix are already helping patients get fast and accurate diagnosis and treatment for a range of serious conditions. Securing this funding will help them to grow, create more jobs, and support more patients. This is not only an example of an excellent university spinout, but also evidence of how the deep pool of tech and life sciences expertise found in Oxford, and across the country, is drawing investment into the UK, driving growth, and supporting our Plan for Change.” John Pearson, Chief Investment Officer at Parkwalk Advisors, said: “The potential for AI-powered platforms in healthcare to revolutionise diagnosis and treatment decisions is clear. Brainomix has successfully demonstrated its platform imaging software is able to deliver both significant societal impact and strong growth for investors. Parkwalk is excited to continue supporting a company that is creating comprehensive solutions to critical needs and implementing them at scale.” Oliver Reuss, Investment Manager of the Boehringer Ingelheim Venture Fund and Director of the Brainomix Board, said: "Brainomix has demonstrated an unparalleled track record of successfully delivering AI solutions into stroke clinical practice, and they are now doing it again in lung fibrosis. As a strategic investor with a shared vision to enhance care for lung disease, we believe Brainomix has the potential to improve the identification and access to treatment for people with lung fibrosis." 🔗 https://lnkd.in/eFd_XfDT LifeSci Advisors, LLC Oxford University Innovation #SeriesC #investment #funding #AI #stroke #lungfibrosis #UK #TransformingTreatment

Parasite control isn’t just about animal health—it’s about public health. 🏥🐾 Some parasites can pass from pets to people, creating risks for families and communities. That’s why more than 30 leading veterinary and parasitology organizations are uniting today on World #ParasiteAwarenessDay to push for stronger awareness and action 👇 https://lnkd.in/ec4DnXev

Early detection policies for individuals at risk should be implemented globally to reduce the healthcare costs associated with kidney failure and improve quality of life. Early detection saves lives! #AreYourKidneysOK? https://lnkd.in/eF-sguYb #WorldKidneyDay #AreYourKidneysOK #KidneyHealthMatters World Health Organization

#DYK these key facts about kidney disease? 🧐 Understanding the risks and getting tested early can make a big difference in protecting your kidney health. Learn more 💡 https://lnkd.in/dhPA7xUF #WorldKidneyDay #AreYourKidneysOK #KidneyHealthMatters

𝗣𝗥𝗘𝗦𝗦 𝗥𝗘𝗟𝗘𝗔𝗦𝗘: 𝗦𝗮𝗹𝗶𝗽𝗿𝗼 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗮𝗻𝗱 Boehringer Ingelheim 𝗘𝗻𝘁𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗟𝗶𝗰𝗲𝗻𝘀𝗲 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝘁𝗼 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗕𝗼𝗲𝗵𝗿𝗶𝗻𝗴𝗲𝗿 𝗜𝗻𝗴𝗲𝗹𝗵𝗲𝗶𝗺 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗣𝗿𝗼𝗴𝗿𝗮𝗺𝘀  The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable and accelerate the development of novel therapeutics. Stockholm, Sweden, March 13, 2025 – Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets. This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases. The partnership leverages Salipro Biotech’s proprietary Salipro® platform technology, which stabilises membrane proteins in their native forms, enabling their use in drug discovery programs. Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), on Boehringer pipeline targets enabled by the Salipro®-technology to identify potential therapeutic candidates. Under the terms of the agreement, Salipro Biotech will receive research payments, option payments and is eligible for downstream success-based milestone payments based on developmental results generated by Boehringer Ingelheim under this collaboration. “We are excited to collaborate with the innovative teams at Boehringer Ingelheim,” said Jens Frauenfeld, CEO of Salipro Biotech. “By combining our Salipro® platform technology with Boehringer Ingelheim’s expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.” 

Kidney disease is a major cause of premature mortality and is expected to become the 5th leading cause of death worldwide. Sign the petition to urge global leaders to make kidney health a priority ✍🏻 https://lnkd.in/eWSAeEAh International Society of Nephrology #WorldKidneyDay #AreYourKidneysOK #KidneyHealthMatters